

Conyers advises HUTCHMED (China) Limited in connection with its HK\$4.553 billion IPO

1 minute read | Deals & Transactions

 [Print Page](#)

Jun 2021

Conyers provided British Virgin Islands and Cayman Islands legal advice to HUTCHMED (China) Limited (“HUTCHMED”) in connection with its HK\$4.553 billion listing on the Main Board of The Stock Exchange of Hong Kong Limited of the shares of HUTCHMED involving a Hong Kong Public Offering and an International Offering (Stock Code : 13).

This was the third listing of the shares of HUTCHMED, in addition to its current listings on Nasdaq and London AIM.

HUTCHMED is a biopharmaceutical company that develops, manufactures and sells pharmaceutical products. They offer drugs for autoimmune diseases and oncology treatment.

Partner Richard Hall, Associate Felicity Lee and Associate Michael Yu of Conyers' Hong Kong office advised on the matter working alongside Freshfields Bruckhaus Deringer, Gibson, Dunn & Crutcher, King & Wood Mallesons and DLA Piper UK LLP.

This matter has been shortlisted for “Deal of the Year – Equity Market” by ALB Hong Kong Law Awards 2022.

Authors



Richard Hall

PARTNER

Hong Kong

T +852 2842 9530

M +852 6469 3355

richard.hall@conyers.com

[LinkedIn](#) | [vCard](#)



Michael Yu

ASSOCIATE

Hong Kong

T +852 2842 9522

M +852 6469 3903

michael.yu@conyers.com

[LinkedIn](#) | [vCard](#)